PLx Pharma Inc Stock News

Dipexium Pharmaceuticals, Inc. (PLXP) delivered earnings and revenue surprises of -5.80% and 17.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for

SPARTA, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinica

SPARTA, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinical

Summers Value Partners, an investment management firm, published its Summers Value Fund fourth quarter 2021 investor letter a copy of which can be downloaded here.

Investors need to pay close attention to Dipexium Pharmaceuticals (PLXP) stock based on the movements in the options market lately.

Upgrades For CarMax Inc (NYSE: KMX ), JP Morgan upgraded the previous rating of Neutral to Overweight. For the second quarter, CarMax had an EPS of $1.72, compared to year-ago quarter EPS of $1.79. The stock has a 52-week-high of $155.98 and a 52-week-low of $90.30. At the end of the last trading period, CarMax closed at $144.50. According to Evercore ISI Group, the prior rating for RPM International Inc (NYSE: RPM ) was changed from In-Line to Outperform. In the first quarter, RPM International showed an EPS of $1.08, compared to $1.44 from the year-ago quarter. The current stock performance of RPM International shows a 52-week-high of $99.30 and a 52-week-low of $76.43. Moreover, at the end of the last trading period, the closing price was at $95.43. According to Evercore ISI Group, the prior rating for PPG Industries Inc (NYSE: PPG ) was changed from In-Line to Outperform. In the third quarter, PPG Industries showed an EPS of $1.69, compared to $1.93 from the year-ago quarter. The stock has a 52-week-high of $182.97 and a 52-week-low of $132.10.

SPARTA, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (PLx or the Company) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 325 mg and VAZALORE 81 mg liquid-filled aspirin capsules (referred to together as VAZALORE), announced today that Natasha Giordano, President and Chief Executive Officer, and Rita OConnor, Chief Financial Officer, are scheduled to present virtually at the Piper Sandler 33rd Annual Healthcare Conference 2021.

SPARTA, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinicall

PLx Pharma Inc. (NASDAQ:PLXP) price on Friday, November 19, fall -3.36% below its previous days close as a downside momentum from buyers pushed the stocks value to $10.07. A look at the stocks price movement, the close in the last trading session was $10.42, moving within a range at $10.02 and $10.70. The beta value PLx Pharma Inc. (PLXP): At $10.07, Its Worth Your Attention Read More »

PLx Pharma Inc. (NASDAQ:PLXP) Equities researchers at BWS Financial reduced their FY2021 earnings per share estimates for shares of PLx Pharma in a note issued to investors on Monday, November 15th. BWS Financial analyst H. Khorsand now expects that the biotechnology company will post earnings per share of ($1.63) for the year, down from []

PLx Pharma (NASDAQ:PLXP) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a research report issued to clients and investors on Thursday, Zacks.com reports. According to Zacks, PLx Pharma Inc. is a specialty pharmaceutical company. It focused on developing clinically validated and patent-protected PLxGuard(TM) delivery system to provide safe []

PLx Pharma Inc. (PLXP) CEO Natasha Giordano on Q3 2021 Results - Earnings Call Transcript

SPARTA, N.J., Nov. 01, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a specialty pharmaceutical company focused on its clinically-validated and patent-pr

Shares of PLx Pharma Inc. PLXP, -9.41% dropped 9.2% in afternoon trading Thursday, but nearly halved their earlier loss, as the drug maker responded to recently raised concerns over the use of aspirin